<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03916913</url>
  </required_header>
  <id_info>
    <org_study_id>NCC201805002</org_study_id>
    <nct_id>NCT03916913</nct_id>
  </id_info>
  <brief_title>TKI Followed by Thoracic Radiotherapy for Stage IV EGFR Mutant NSCLC</brief_title>
  <official_title>Tyrosine Kinase Inhibitor Followed by Thoracic Radiotherapy for Stage IV EGFR Mutant Non-small Cell Lung Cancer: A Phase II Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this phase II trial with single arm, we aim to investigate the clinical efficacy and&#xD;
      toxicity profile of local radiotherapy on all disease sites for EGFR-mutant oligo-metastatic&#xD;
      NSCLC (no more than 3 metastatic lesions) who did not experience disease progression after at&#xD;
      least 3 months of TKI therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tyrosine kinase inhibitor (TKI) has been widely accepted as the first-line therapy for stage&#xD;
      IV NSCLC with active mutation of EGFR. Olio-metastasis is a disease status between localized&#xD;
      and extended status of disease, namely with the limited number of lesions, which is generally&#xD;
      defined as ≤ 5. A couple of phase II studies have shown that consolidation local management&#xD;
      was able to prolong the local-regional tumor control and might further improve overall&#xD;
      survival (OS) for oligo-metastatic NSCLC who have gained disease control from systemic&#xD;
      therapy. However, there is lack of data regarding whether local radiotherapy (RT) could&#xD;
      improve progression free survival (PFS) and OS for NSCLC with active EGFR mutation who have&#xD;
      benefited from TKI. In this phase II trial with single arm, we aim to investigate the&#xD;
      clinical efficacy and toxicity profile of local radiotherapy on all disease sites for&#xD;
      EGFR-mutant oligo-metastatic NSCLC (no more than 3 metastatic lesions) who did not experience&#xD;
      disease progression after at least 3 months of TKI therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>1 year</time_frame>
    <description>Duration between the first date of TKI administration and disease progression or last follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response</measure>
    <time_frame>1 month after RT</time_frame>
    <description>Post-RT response compared with the baseline status at the first data of TKI administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 year</time_frame>
    <description>Duration between the first date of TKI administration and any cause of death or last follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression of initial lesions</measure>
    <time_frame>1 year</time_frame>
    <description>Duration between the first date of TKI administration and the progression of the initial lesions or last follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to appearance of new metastatic lesions</measure>
    <time_frame>1 year</time_frame>
    <description>Duration between the first date of TKI administration and the occurrence of new lesions or last follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment related toxicity</measure>
    <time_frame>1 year</time_frame>
    <description>Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EORTC Quality of life</measure>
    <time_frame>1 year</time_frame>
    <description>Quality of life evaluation using EORTC questionnaires</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">85</enrollment>
  <condition>Non-Small Cell Lung Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Local therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Consolidation local radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Local radiation therapy</intervention_name>
    <description>Local radiotherapy on all sites of disease including primary and metastatic lesions</description>
    <arm_group_label>Local therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 and ≤75;&#xD;
&#xD;
          -  ECOG performance status 0-1;&#xD;
&#xD;
          -  Patients must provide study specific informed consent prior to study entry;&#xD;
&#xD;
          -  Pathologically or cytologically diagnosed as NSCLC;&#xD;
&#xD;
          -  EGFR activating mutation to TKI approved by histology, cytology or circulation tumor&#xD;
             DNA;&#xD;
&#xD;
          -  Stage IV NSCLC with ≤ 3 metastatic lesions (AJCC, 8th ed.) confirmed by meticulous&#xD;
             radiographic examination. Brain MRI and 18F PET/CT is strongly recommended unless&#xD;
             there is a contraindication;&#xD;
&#xD;
          -  Patients have received≥3 months of TKI therapy and do not received disease&#xD;
             progression;&#xD;
&#xD;
          -  HB ≥ 10.0 g/dL;&#xD;
&#xD;
          -  Absolute number of neutrophil granulocyte ≥ 1.5 × 109/L;&#xD;
&#xD;
          -  Absolute number of PLT ≥ 100 × 109/L;&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 folds of the maximum extent;&#xD;
&#xD;
          -  ALT and AST ≤ 2.0 folds of the maximum extent;&#xD;
&#xD;
          -  Cr ≤ 1.25 folds of the maximum extent and Ccr ≥ 60mLl/min.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients have received thoracic radiotherapy before;&#xD;
&#xD;
          -  Malignant pleural effusion, pericardial effusion or peritoneal effusion;&#xD;
&#xD;
          -  Patients have severe pulmonary comorbidity, such as ILD, COPD or other active&#xD;
             pulmonary disease;&#xD;
&#xD;
          -  Any unstable systemic disease including active infection, uncontrolled hypertension,&#xD;
             unstable angina, CHF (NYHA ≥ II), MI within 6 months of enrollment, severe arrhythmia&#xD;
             requiring medication，hepatic, nephric or metabolic disease;&#xD;
&#xD;
          -  HIV infection；&#xD;
&#xD;
          -  Pregnancy or lactation women;&#xD;
&#xD;
          -  ECOG status ≥2；&#xD;
&#xD;
          -  Mixed SCLC component;&#xD;
&#xD;
          -  Other factors that is considered ineligible.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jingbo Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Hospital, CAMS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jingbo Wang, MD</last_name>
    <phone>+861087788056</phone>
    <email>wangjingbo303@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaotong Lu, MD</last_name>
    <phone>+861087788503</phone>
    <email>lxt0115@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer Hospital/Institute, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jingbo Wang, Dr.</last_name>
      <phone>8610-87788503</phone>
      <email>wangjingbo303@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Luhua Wang, Dr.</last_name>
      <phone>8610-87788799</phone>
      <email>wlhwq@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jingbo Wang, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luhua Wang, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhouguang Hui, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>JianYang Wang, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 13, 2019</study_first_submitted>
  <study_first_submitted_qc>April 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2019</study_first_posted>
  <last_update_submitted>April 16, 2019</last_update_submitted>
  <last_update_submitted_qc>April 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Jingbo Wang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Non small cell lung cancer</keyword>
  <keyword>Oligo-metastasis</keyword>
  <keyword>EGFR activating mutation</keyword>
  <keyword>Radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

